Morgan Stanley analyst Drew Ranieri lowered the firm’s price target on Alphatec to $16 from $19 and keeps an Overweight rating on the shares. Based on the firm’s channel checks and discussions with corporates, it thinks Medical Technology, or MedTech, fundamentals look solid heading into Q2, with utilization and volumes still running comparatively high across end-markets. While fundamentals and the environment are good, “positioning probably matters more” as the firm suspects idiosyncratic stock positioning and expectations to be “the key driver of price performance on the day, particularly where shorter-duration money is at play,” the analyst added in a preview for the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATEC:
- Alphatec price target lowered to $19 from $24 at Stifel
- Domino’s Pizza upgraded, Bumble downgraded: Wall Street’s top analyst calls
- Alphatec initiated with an Overweight at Barclays
- Alphatec general counsel Marshall sells 50,232 common shares
- Needham medtech/diagnostic analyst holds analyst/industry conference call